Literature DB >> 20124176

Comparison of the prognostic value of assessing tumor diameter versus tumor volume at diagnosis or in response to initial chemotherapy in rhabdomyosarcoma.

Andrea Ferrari1, Rosalba Miceli, Cristina Meazza, Michela Casanova, Francesca Favini, Carlo Morosi, Giovanna Trecate, Alfonso Marchianò, Roberto Luksch, Graziella Cefalo, Monica Terenziani, Filippo Spreafico, Daniela Polastri, Marta Podda, Serena Catania, Elisabetta Schiavello, Patrizia Giannatempo, Lorenza Gandola, Maura Massimino, Luigi Mariani.   

Abstract

PURPOSE: In this study on a series of 205 patients with rhabdomyosarcoma, we investigated whether the prognostic effect of tumor size, at diagnosis or in terms of tumor response after induction chemotherapy, differed when tumor diameter or tumor volume were considered. PATIENTS AND METHODS: Tumor size was assessed radiologically at diagnosis and, for the 108 patients with measurable disease, after three courses of chemotherapy. The analysis was based on multivariable models (linear for association between size and patient/tumor characteristics, Cox for association with survival). The predictive performance of the Cox model (estimated by V measure) was compared for the tumor's diameter and volume.
RESULTS: Initial tumor size was significantly larger in male or older patients and in T2 or alveolar tumors, but was not associated with the achievement of complete surgical resection. Initial tumor size significantly influenced overall survival. The risk of death was comparable for tumors 10 cm in maximum diameter and 194.0 cm(3) in volume. The predictive performance of the Cox model was much the same when the tumor's diameter or volume was considered. Tumor response was a significant predictor of survival, again irrespective of the type of tumor measurement considered.
CONCLUSION: In our analysis, initial tumor size and tumor response were significant prognostic factors in rhabdomyosarcoma, regardless of whether tumor diameter or volume was considered. Three-dimensional tumor assessment was of no greater prognostic value than one-dimensional assessment, neither initially nor after induction treatment.

Entities:  

Mesh:

Year:  2010        PMID: 20124176     DOI: 10.1200/JCO.2009.25.0803

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  21 in total

1.  Worse Outcomes for Head and Neck Rhabdomyosarcoma Secondary to Reduced-Dose Cyclophosphamide.

Authors:  Dana L Casey; Leonard H Wexler; Suzanne L Wolden
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-11-30       Impact factor: 7.038

2.  Overexpression of nuclear β-catenin at invasive front in rectal carcinoma is associated with lymph node metastasis and poor prognosis.

Authors:  L Wang; X Zhang; Z Li; J Chai; G Zhang; Z Yu; Y Cheng; S Hu
Journal:  Clin Transl Oncol       Date:  2013-09-17       Impact factor: 3.405

3.  Assessment of Primary Site Response in Children With High-Risk Neuroblastoma: An International Multicenter Study.

Authors:  Rochelle Bagatell; Kieran McHugh; Arlene Naranjo; Collin Van Ryn; Chaim Kirby; Penelope Brock; Karen A Lyons; Lisa J States; Yesenia Rojas; Alexandra Miller; Sam L Volchenboum; Thorsten Simon; Barbara Krug; Sabine Sarnacki; Dominique Valteau-Couanet; Dietrich von Schweinitz; Birgit Kammer; Claudio Granata; Luca Pio; Julie R Park; Jed Nuchtern
Journal:  J Clin Oncol       Date:  2016-01-11       Impact factor: 44.544

4.  Assessment of objective responses using volumetric evaluation in advanced thymic malignancies and metastatic non-small cell lung cancer.

Authors:  Jeremy Force; Arun Rajan; Eva Dombi; Seth M Steinberg; Giuseppe Giaccone
Journal:  J Thorac Oncol       Date:  2011-07       Impact factor: 15.609

Review 5.  What is new in rhabdomyosarcoma management in children?

Authors:  Yasmin Gosiengfiao; Jennifer Reichek; David Walterhouse
Journal:  Paediatr Drugs       Date:  2012-12-01       Impact factor: 3.022

6.  Three-dimensional Radiologic Assessment of Chemotherapy Response in Ewing Sarcoma Can Be Used to Predict Clinical Outcome.

Authors:  Maryam Aghighi; Justin Boe; Jarrett Rosenberg; Rie Von Eyben; Rakhee S Gawande; Philippe Petit; Tarsheen K Sethi; Jeremy Sharib; Neyssa M Marina; Steven G DuBois; Heike E Daldrup-Link
Journal:  Radiology       Date:  2016-03-16       Impact factor: 11.105

7.  Local failure in parameningeal rhabdomyosarcoma correlates with poor response to induction chemotherapy.

Authors:  Matthew M Ladra; Henry C Mandeville; Andrzej Niemierko; Timothy P Padera; Alison M Friedmann; Shannon M MacDonald; David Ebb; Yen-Lin Chen; Nancy J Tarbell; Torunn I Yock
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-04-08       Impact factor: 7.038

Review 8.  Diagnosis and Management of Rhabdomyosarcoma in Children and Adolescents: ICMR Consensus Document.

Authors:  Saroj Prasad Panda; Girish Chinnaswamy; Tushar Vora; Maya Prasad; Deepak Bansal; Gauri Kapoor; Venkatraman Radhakrishnan; Sandeep Agarwala; Siddharth Laskar; Brijesh Arora; Tanvir Kaur; G K Rath; Sameer Bakhshi
Journal:  Indian J Pediatr       Date:  2017-04-05       Impact factor: 1.967

9.  Tumor volume and patient weight as predictors of outcome in children with intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group.

Authors:  David A Rodeberg; Julie A Stoner; Norbert Garcia-Henriquez; R Lor Randall; Sheri L Spunt; Carola A Arndt; Simon Kao; Charles N Paidas; Lynn Million; Douglas S Hawkins
Journal:  Cancer       Date:  2010-12-14       Impact factor: 6.860

10.  Early response as assessed by anatomic imaging does not predict failure-free survival among patients with Group III rhabdomyosarcoma: a report from the Children's Oncology Group.

Authors:  Abby R Rosenberg; James R Anderson; Elizabeth Lyden; David A Rodeberg; Suzanne L Wolden; Simon C Kao; David M Parham; Carola Arndt; Douglas S Hawkins
Journal:  Eur J Cancer       Date:  2013-12-18       Impact factor: 9.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.